Onconova Therapeutics, Inc.
375 Pheasant Run
Newtown, PA 18954
February 6, 2018
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
|
Attention: |
|
Christine Westbrook |
|
|
|
Erin Jaskot |
|
Re: |
|
Onconova Therapeutics, Inc. |
|
|
|
Registration Statement on Form S-1 (File No. 333-222374) |
|
|
|
Request for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Onconova Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced registration statement, as amended (the “Registration Statement”), so that the Registration Statement may become effective at 5:15 p.m. (Eastern Time) on February 7, 2018, or as soon as practicable thereafter.
Once the Registration Statement has been declared effective, please orally confirm that event with Joanne R. Soslow of Morgan, Lewis & Bockius LLP at (215) 963-5262.
Under separate cover, you will receive today a letter from the underwriter of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement.
|
ONCONOVA THERAPEUTICS, INC. |
| |
|
|
| |
|
By: |
/s/ MARK GUERIN |
|
|
Name: |
Mark Guerin |
|
|
Title: |
Chief Financial Officer |
|